Figure 2D shows that the percentage of tumor-free mice in CD8+ or CD4+ T cell depleted groups (12.5% and 37.5%, respectively), 3 weeks after vaccination with TSA-treated B16 cells, is significantly lower than the control groups (~75%). The gene discussed is CD8A; the disease is neoplasm.